Dr Aly-Khan Lalani speaks to ecancer about the CYTOSHRINK trial.

This trial evaluated stereotactic body radiation therapy (SBRT) to the primary kidney lesion combined with ipilimumab and nivolumab versus ipilimumab or nivolumab alone in previously untreated de novo metastatic renal cell carcinoma (mRCC).

Among 67 randomised patients (43 ipilimumab/nivolumab+SBRT, 24 ipilimumab/nivolumab alone) with IMDC intermediate or poor risk, 12-month progression-free survival was 35% vs 48% (HR 1.29), objective response rate was 33% vs 42%, and 18-month overall survival was 59% vs 70% for ipilimumab/nivolumab plus SBRT versus ipilimumab/nivolumab alone.

While early SBRT did not improve progression-free survival, the combination was safe, and further analyses of overall survival, quality of life, and correlative biomarkers are ongoing.